Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for the first half of 2023, following the completion of the separation of its consumer healthcare spinoff, Kenvue (NYSE: KVUE), into an independent company. The document reveals that H1 2023 global sales reached USD 42.4 billion, marking a 6.4% year-on-year (YOY) adjusted operational increase.
Pharmaceutical and Medical Technology Units’ Contribution
Pharmaceutical subsidiary Janssen led the way with a 5.6% YOY increase in adjusted terms, contributing USD 27.1 billion to the total sales. The medical technology unit also performed well, reaching USD 15.3 billion, up 8.1% YOY.
Geographical Sales Performance
In terms of geographical contributions, the United States, J&J’s home market, accounted for USD 22.4 billion with a 10.2% YOY operational growth in the first six months. The rest of the Americas region saw a significant increase of 16.2%, reaching USD 2.2 billion. The European market expanded by 2.1% to USD 10.7 billion, and the Asia-Pacific and Africa region experienced an 8.5% rise, contributing USD 7.0 billion to the total sales.-Fineline Info & Tech
